SA517380723B1 - rHu-GCSF طريقة لتنقية - Google Patents

rHu-GCSF طريقة لتنقية

Info

Publication number
SA517380723B1
SA517380723B1 SA517380723A SA517380723A SA517380723B1 SA 517380723 B1 SA517380723 B1 SA 517380723B1 SA 517380723 A SA517380723 A SA 517380723A SA 517380723 A SA517380723 A SA 517380723A SA 517380723 B1 SA517380723 B1 SA 517380723B1
Authority
SA
Saudi Arabia
Prior art keywords
purification
rhu
gcsf
csf
scalable
Prior art date
Application number
SA517380723A
Other languages
English (en)
Inventor
ارجون راجهوانشى،
نيدهيبين زاكر،
سانجاى سينج،
شراوان كومار سينج،
شاجن شانكار،
بافان كارديل،
Original Assignee
جينوفا بيوفارماسيوتيكالز ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by جينوفا بيوفارماسيوتيكالز ليمتد filed Critical جينوفا بيوفارماسيوتيكالز ليمتد
Publication of SA517380723B1 publication Critical patent/SA517380723B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

يعمل الاختراع الحالي على إعداد، طريقة جديدة، قابلة للتطوير والتطبيق الصناعي لتيار منخفض وذلك لتنقية G-CSF البشري المأشوب (المؤتلف). شكل 1
SA517380723A 2014-07-14 2017-01-14 rHu-GCSF طريقة لتنقية SA517380723B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2289MU2014 2014-07-14
PCT/IN2015/050066 WO2016009451A2 (en) 2014-07-14 2015-07-13 A novel process for purification of rhu-gcsf

Publications (1)

Publication Number Publication Date
SA517380723B1 true SA517380723B1 (ar) 2021-05-18

Family

ID=55079140

Family Applications (1)

Application Number Title Priority Date Filing Date
SA517380723A SA517380723B1 (ar) 2014-07-14 2017-01-14 rHu-GCSF طريقة لتنقية

Country Status (13)

Country Link
US (1) US10519209B2 (ar)
EP (1) EP3169697A4 (ar)
JP (1) JP6742300B2 (ar)
AU (1) AU2015291123C1 (ar)
BR (1) BR112017000704A2 (ar)
CL (1) CL2017000087A1 (ar)
CO (1) CO2017001387A2 (ar)
EA (1) EA035448B1 (ar)
MX (1) MX2017000467A (ar)
NZ (1) NZ728662A (ar)
PE (2) PE20220371A1 (ar)
SA (1) SA517380723B1 (ar)
WO (1) WO2016009451A2 (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
CN109840410B (zh) * 2017-12-28 2021-09-21 中国科学院计算技术研究所 一种进程内数据隔离与保护的方法和***
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
JP2022529811A (ja) * 2019-04-24 2022-06-24 タンベックス バイオファーマ ユーエスエー，インコーポレイティド 顆粒球コロニー刺激因子を調製するためのプロセス
WO2022167886A1 (en) * 2021-02-04 2022-08-11 Intas Pharmaceuticals Ltd. An improved peg-gcsf purification process having dual ufdf
WO2022245259A1 (ru) * 2021-05-18 2022-11-24 Акционерное общество "ГЕНЕРИУМ" Способ промышленной очистки ромиплостима

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ218336A (en) 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
EP1881005B1 (en) * 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
CN1663962A (zh) 2004-03-01 2005-09-07 重庆富进生物医药有限公司 重组人粒细胞集落刺激因子及其化学修饰物的一步纯化工艺
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
DE102005033250A1 (de) * 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
US7790862B2 (en) * 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
RS53010B (en) * 2009-12-31 2014-04-30 Arven Ilac Sanayi Ve Ticaret A.S. NEW PROCEDURE FOR PREPARATION OF G-CSF (GRANULOCITE COLONY STIMULATION FACTOR)
CN102234310B (zh) 2010-04-30 2017-02-08 杭州九源基因工程有限公司 一种聚乙二醇修饰蛋白的分离纯化方法
RU2446173C1 (ru) * 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
KR101831300B1 (ko) * 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
CN102485742A (zh) * 2010-12-02 2012-06-06 山东新时代药业有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
EP2670424A4 (en) * 2011-02-01 2014-12-31 Fate Therapeutics Inc CARDIOTROPHINE-RELATED MOLECULES FOR ENHANCED THERAPEUTICS
US9422354B2 (en) * 2012-06-19 2016-08-23 Indian Institute Of Technology Delhi Process for purification of recombinant granulocyte colony stimulating factor (rHu GCSF)

Also Published As

Publication number Publication date
AU2015291123C1 (en) 2020-12-10
PE20170769A1 (es) 2017-07-04
US10519209B2 (en) 2019-12-31
AU2015291123B2 (en) 2020-03-12
AU2015291123A1 (en) 2017-02-23
EA201700058A1 (ru) 2017-07-31
NZ728662A (en) 2021-01-29
EP3169697A2 (en) 2017-05-24
CO2017001387A2 (es) 2017-05-10
PE20220371A1 (es) 2022-03-16
BR112017000704A2 (pt) 2017-11-14
JP6742300B2 (ja) 2020-08-19
EP3169697A4 (en) 2017-11-08
US20170210784A1 (en) 2017-07-27
MX2017000467A (es) 2017-07-28
WO2016009451A3 (en) 2016-05-19
JP2017526649A (ja) 2017-09-14
EA035448B1 (ru) 2020-06-17
WO2016009451A2 (en) 2016-01-21
CL2017000087A1 (es) 2018-05-18

Similar Documents

Publication Publication Date Title
AU2024202215A1 (en) Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
PH12017501365B1 (en) Novel promoter and uses thereof
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
SA517380723B1 (ar) rHu-GCSF طريقة لتنقية
MX2016012371A (es) Anticuerpos multiespecificos.
IN2014CH00247A (ar)
HUE059279T2 (hu) Eljárás alkének elõállítására és azok felhasználása 1,3-butadién elõállításához
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
MX2017002538A (es) Absorbedor para unión de metales y la producción del mismo.
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2016017367A (es) Dioxido de zirconio, producto refractario, uso de dioxido de zirconio, procedimiento para la fabricacion de un producto refractario asi como un producto refractario fabricado mediante el mismo.
MX2019002778A (es) Procedimiento de hidrogenacion.
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
MX2017006692A (es) Trastornos neurodegenerativos.
MX2017008776A (es) Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario.
MX2017001805A (es) Combinacion ceramica refractaria asi como producto ceramico refractario.
MX2016014255A (es) Producto ceramico refractario.
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
MY187078A (en) Process of production of 7,8-dihydro-c15-aldehyde
HRP20181123T1 (hr) Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac
IN2014MU01191A (ar)
MX2018001296A (es) Proceso para la sintesis de ravidasvir.
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния